EHMT1 and neoplasm: Since both G9a/GLP and HDAC enzymes are overexpressed in several cancers and given their role in the tumor growth and progression, scientists developed dual inhibitors incorporating the pharmacophores of G9a/GLP and HDAC inhibitors to simultaneously block both the oncogenic targets to harvest the synergistic action of the resulting hybrids.